Valneva (NASDAQ:VALN) Stock Price Down 11.2% – What’s Next?

Valneva SE (NASDAQ:VALN)’s share price fell 11.2% during trading on Friday . The company traded as low as $6.87 and last traded at $6.92. 79,836 shares traded hands during trading, an increase of 30% from the average session volume of 61,567 shares. The stock had previously closed at $7.79.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Valneva in a report on Friday, January 31st.

Valneva Trading Down 10.1 %

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business has a 50 day moving average price of $4.87 and a 200-day moving average price of $5.67. The company has a market cap of $569.23 million, a P/E ratio of -53.88 and a beta of 1.98.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. ABC Arbitrage SA bought a new stake in shares of Valneva in the 4th quarter valued at about $84,000. AlphaCentric Advisors LLC increased its position in Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock worth $717,000 after buying an additional 29,748 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after buying an additional 30,859 shares during the period. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.